Contact : Terrence Kopp (612) 327-3700
Sound Choice Pharmaceutical Institute
Molecular and Cellular Scientist to address Vaccine safety issues in Minnesota Thursday
ST. PAUL, MN – Dr Theresa Deisher, Ph D, Stanford, founder of AVM Biotechnology and Sound Choice Pharmaceuticals, will visit the Twin Cities again this Thursday, April 28, in a continuation of her public efforts to shed light on key elements regarding vaccine safety, specifically as regards the likely adverse affects of human DNA residuals in many widely utilized vaccines.
Dr Deisher’s formal testimony will anchor a special formal information committee meeting of the MN House Health and Human Services Reform Committee on Thursday, April 28, at 12:30. Minnesota Health Commissioner Dr Edward Ehlinger and key staff will meet with Dr Deisher immediately following her committee testimony. Dr Deisher had met in April 2010 with previous Health Commissioner Dr Sanne Magnan and staff on similar topics. There is a public education presentation and Q and A session, entitled “Vaccine Safety, New Considerations, Concerns and Insights”, scheduled for 7 – 9 PM on Thursday evening at the Minneapolis Central Library, in the Doty Board Room, 300 Nicollet Mall. Press representatives are welcome.
In January, 2001, the US Department of Health and Human Services Interagency Autism Coordinating Committee (IACC) released a Strategic Plan for Autism Disorder Research. In this plan they accept the June 2009 recommendations of the National Vaccine Advisory Committee to support additional studies into the link between vaccines and autism disorders. The IACC strategic plan states that biological agents may confer environmental risk. Human DNA residuals in vaccines constitute such a biological agent. Sound Choice Pharmaceutical Institute , under Dr Deisher’s direction, is conducting cutting edge research in this realm in support of the goals of the IACC and the National Vaccine Advisory Committee.
Theresa Diesher Biography:
Theresa Deisher, Ph.D.
President, Founder, Sound Choice Pharmaceutical Institute
Dr. Deisher, an internationally renowned expert in the field of adult stem cell therapies and regenerative medicine, brings 17 years of experience in scientific and corporate leadership positions involving research, discovery, production and commercialization of human therapeutics. Dr. Deisher’s penchant for groundbreaking scientific discovery and her distinguished scientific research has resulted in 23 patents issued. She has published numerous scientific manuscripts and is a frequent invited lecturer and guest speaker in the area of stem cell technology and regenerative medicine.
Throughout her career, Dr. Deisher has been recruited by some of the country’s top biotechnology companies, including Genentech, Repligen, ZymoGenetics, Immunex and Amgen. She has managed and mentored undergraduate honors students, post-doctoral fellows, scientific executives and over 20 research assistants/scientists at all levels of responsibility.
Dr. Deisher graduated with honors and distinction from Stanford University, and obtained her Ph.D. in Molecular and Cellular Physiology from Stanford University.
Subsequent to obtaining her Ph.D from Stanford, Dr. Deisher was recruited by Repligen Corporation (Cambridge, MA) and accepted a position as Research Scientist where she managed a staff of associates and scientists and directed the development of research and clinical assays in support of Phase I and Phase II clinical trials for various Repligen developmental efforts. Additionally, Dr. Deisher was selected by Sr. Management to participate in strategic alliance initiatives, including serving on the Repligen / Eily Lilly joint development committee.
Following Repligen, Dr. Deisher accepted a position at ZymoGenetics, Inc (Seattle, WA) as Sr. Scientist, Cardiovascular Biology. While at ZymoGenetics, Dr. Deisher’s research and discovery in the area of cardiovascular biology led to the filing of dozens of patents. Dr. Deisher was the first person world-wide to identify and patent stem cells from the adult heart, including what are now called ‘very small embryonic-like stem cells’. Her discovery remains one of the most significant discoveries in the area of stem cell research. Within the field of regenerative medicine, Dr. Deisher is also a patented inventor of the most potent mesenchymal growth factor ever identified (licensed to Serono for clinical development), and of the use of cytokines to mobilize adult embryonic-like cells.
Following ZymoGenetics, Dr. Deisher was named Sr. Staff Scientist, Vascular Biology at Immunex (Seattle, WA) where she was the project leader for both the Antithrombotic division and the Inflammation and Myocardial Repair division.
Dr. Deisher was named Principal Scientist at Amgen, Inc. (Seattle, WA) following Amgen’s acquisition of Immunex. She led multi-disciplinary teams working on the biology and commercial development of novel co-stimulatory pathways involved in the initiation and progression of cardiac failure. Her research interests encompassed stem cell therapies for myocardial regeneration. Additionally, Dr Deisher introduced revolutionary non-invasive imaging technologies for pre-clinical research to the company, including ultrasound (echocardiography) and near-infrared imaging. As a result, the company was honored as an official ‘Site of Excellence’ by Philips Medical for her department’s pioneering work.
Most recently, Dr. Deisher served as Vice President of Research and Development for Cellcyte Genetics Corporation, a post she held until October 2007 prior to founding AVM Biotechnology LLC, and the not for profit Sound Choice Pharmaceutical Institute.